Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) CEO Eric Venker sold 200,000 shares of the firm's stock in a transaction dated Monday, July 27th. The shares were sold at an average price of $34.95, for a total value of $6,990,000.00. Following the transaction, the chief executive officer owned 1,613,063 shares of the company's stock, valued at $56,376,551.85. This trade represents a 11.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Eric Venker also recently made the following trade(s):
- On Wednesday, June 24th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $33.16, for a total transaction of $6,632,000.00.
- On Friday, May 22nd, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $30.27, for a total transaction of $6,054,000.00.
Roivant Sciences Stock Performance
NASDAQ ROIV opened at $32.87 on Thursday. The firm has a market cap of $23.64 billion, a price-to-earnings ratio of -54.78 and a beta of 1.11. The firm has a 50 day simple moving average of $32.48 and a 200-day simple moving average of $28.93. Roivant Sciences Ltd. has a one year low of $10.90 and a one year high of $37.00.
Hedge Funds Weigh In On Roivant Sciences
Several large investors have recently bought and sold shares of ROIV. Handelsbanken Fonder AB raised its stake in Roivant Sciences by 51.4% in the second quarter. Handelsbanken Fonder AB now owns 177,209 shares of the company's stock valued at $6,271,000 after buying an additional 60,200 shares in the last quarter. Assenagon Asset Management S.A. boosted its position in shares of Roivant Sciences by 18.2% during the 2nd quarter. Assenagon Asset Management S.A. now owns 8,362,952 shares of the company's stock worth $295,965,000 after acquiring an additional 1,286,464 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Roivant Sciences by 17.4% during the 2nd quarter. GAMMA Investing LLC now owns 14,637 shares of the company's stock worth $518,000 after acquiring an additional 2,172 shares in the last quarter. Versant Capital Management Inc increased its holdings in shares of Roivant Sciences by 13.9% in the 2nd quarter. Versant Capital Management Inc now owns 3,995 shares of the company's stock valued at $141,000 after acquiring an additional 487 shares during the last quarter. Finally, Pacer Advisors Inc. increased its holdings in shares of Roivant Sciences by 37.1% in the 1st quarter. Pacer Advisors Inc. now owns 96,303 shares of the company's stock valued at $2,668,000 after acquiring an additional 26,044 shares during the last quarter. Hedge funds and other institutional investors own 64.76% of the company's stock.
Wall Street Analyst Weigh In
Several equities analysts have commented on the stock. HC Wainwright reissued a "buy" rating and issued a $34.00 price target on shares of Roivant Sciences in a research report on Thursday, May 21st. TD Cowen boosted their price objective on Roivant Sciences from $38.00 to $41.00 and gave the stock a "buy" rating in a research report on Thursday, May 21st. Guggenheim upped their target price on shares of Roivant Sciences from $30.00 to $36.00 and gave the stock a "buy" rating in a research note on Tuesday, May 26th. Weiss Ratings cut shares of Roivant Sciences from a "sell (d)" rating to a "sell (d-)" rating in a report on Friday, May 22nd. Finally, Leerink Partners set a $42.00 price target on shares of Roivant Sciences in a research note on Thursday, May 21st. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Roivant Sciences has an average rating of "Moderate Buy" and a consensus price target of $33.59.
Check Out Our Latest Analysis on Roivant Sciences
About Roivant Sciences
(
Get Free Report)
Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.
The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
